Long-term outcome of detectable PSA levels after radical prostatectomy

Prostate Cancer Prostatic Dis. 2005;8(2):163-6. doi: 10.1038/sj.pcan.4500788.

Abstract

Detectable prostate-specific antigen levels (PSA) following radical prostatectomy (RP) are believed to represent treatment failure. In this retrospective review, we characterize long-term PSA outcomes following RP (n = 204) in a non-referral hospital performed between 1984 and 1994. With an average follow-up of 10 y, 90 (44%) patients developed a PSA recurrence: 15 (17%) died of prostate cancer despite hormonal intervention, 39 (43%) responded to hormonal therapy with stable remission and 36 (40%) were observed without intervention. Following RP many patients may have a detectable PSA that does not require treatment. PSA doubling time (< 12 months) was the best predictor of disease progression.

MeSH terms

  • Aged
  • Disease Progression
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local*
  • Predictive Value of Tests
  • Prostate-Specific Antigen / blood*
  • Prostatectomy*
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery*
  • Retrospective Studies

Substances

  • Prostate-Specific Antigen